News & Analysis on Clinical Trial Services & Contract Research And Development
Lonza has been authorised by the US Food and Drug Administration (FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia (abatacept), in what is shaping up to be a major manufacturing deal for the Swiss company.
German biopharmaceutical company Boehringer Ingelheim has clinched a licencing deal for XstalBio's formulation and stabilisation technology which can be applied to the delivery of biomolecules via a number of routes, including pulmonary, as well as...
The laboratory identification of promising candidates for new anti-cancer drugs is to be made significantly easier after scientists developed a litmus test that determines the bonding strength of DNA, small molecules and proteins to DNA.
The boom in advanced drug delivery devices is creating demand for specialist manufacturers that can rise to the challenge of making these complicated devices, although such companies are currently thin on the ground.
Private US biosciences company Codexis has acquired the assets of private Dutch company Enzis. Included in the deal are the patents to several new classes of enzymes that Codexis will use to develop cheaper and faster drug manufacturing processes.
Vandalia Research has launched a new DNA amplification service that it claims will speed up the mass production of high-quality DNA sequences with the polymerase chain reaction (PCR), while at the same time reducing the risk of contamination.
Skyepharma has finally found a partner to license and market its new asthma drug delivery product after over a year of searching and one big-pharma partnership that went belly up in 2005 - giving the company new hope of revamping falling profits.
Kendle has seized a chance to expand and diversify its business, snapping up the Phase II-IV Clinical Services unit of Charles River Laboratories after it decided to get out of this area of clinical trial services and focus instead on its core drug...